Alice Tsai

Alice Tsai serves as Executive Director and Head of DMPK and Preclinical Safety at Tango Therapeutics since June 2021, following a distinguished 13-year tenure at Vertex Pharmaceuticals, where roles included Senior Director and Director, leading various teams in translational PKPD, bioanalytical, and in vivo research. Prior positions at Vertex Pharmaceuticals comprised Associate Director, Fellow I, Senior Scientist, Scientist II, and Scientist I, all focused on preclinical PKPD modeling and DMPK projects. Alice Tsai earned a PhD in Pharmaceutical Sciences and an M.S. in Nutrition and Exercise Sciences from the University at Buffalo, as well as a B.S. in Agricultural Chemistry from National Taiwan University, and participated in the Women Unlimited program from 2013 to 2014.